Novavax, Inc. (BMV: NVAX)

Market Cap	27.88B
Revenue (ttm)	17.33B
Net Income (ttm)	-5.58B
Shares Out	n/a
EPS (ttm)	-38.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,939
Open	179.00
Previous Close	176.56
Day's Range	179.00 - 184.00
52-Week Range	65.10 - 390.00
Beta	n/a
RSI	47.05
Earnings Date	Feb 28, 2025

About Novavax

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand n...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 1,543
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: NVAX

Financial Performance

In 2023, Novavax's revenue was $983.71 million, a decrease of -50.36% compared to the previous year's $1.98 billion. Losses were -$545.06 million, -17.16% less than in 2022.

Financial numbers in USD